Swiss Biotech IPOs May Revive Industry Starved of Investment
This article is for subscribers only.
Swiss biotechnology share sales may help kick-start an industry where investment has slumped by more than two-thirds in the past four years.
Molecular Partners, a Zurich-based firm with an experimental eye medicine in mid-stage testing, is among the companies tipped by analysts for Switzerland’s first biotech initial public offering in four years. The closely held company, formed by a group of researchers from the University of Zurich, started operations in 2005 and counts Johnson & Johnson’s venture-capital arm among its investors.